BNTCNasdaqPharmaceutical PreparationsFiscal year ends June 30

Benitec Biopharma Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 14, 2026

$8.36+0.25 (+3.08%)

Close on Oct 19, 2026

Market cap: $413.29M
P/E (TTM): –
Dividend yield: –

Benitec Biopharma Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30
Depreciation & Amortization	0.06	0.07	0.09	0.14	0.17	0.23	0.19	0.16
Stock-Based Compensation	26	17	0.83	0.45	0.87	0.63	0.24	0.67
Change in Accounts Receivable	0.03	0.20	-0.18	-0.05	0.00	0.03	2.40	0.61
Operating Cash Flow	-17	-24	-19	-18	-16	-13	-7.54	4.79
Capital Expenditures	-0.11	-0.02	-0.18	0.00	-0.01	-0.22	-0.10	-0.40
Sale of Property, Plant & Equipment	–	–	–	–	–	–	0.00	0.00
Investing Cash Flow	-0.11	-0.02	-0.18	0.00	-0.01	-0.22	-0.09	-0.40
Stock Issued	104	30	–	18	–	26	2.25	–
Financing Cash Flow	99	70	68	16	–	23	1.77	–
Foreign Exchange Rate Adjustments	-0.13	0.05	-0.01	0.41	0.20	0.50	-0.06	-0.55
Net Change in Cash	82	47	48	-1.59	-16	9.97	–	–
Free Cash Flow	-17	-24	-20	-18	-16	-13	-7.63	4.39

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -33.2%

Financial strength

Current ratio: 34.00
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3367.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.33
Dividend yield: –